Kesimpta® (ofatumumab) granted European and UK license for relapsing multiple sclerosis

Written by Neuro Central

Novartis (London, UK) has announced that the Medicines and Healthcare products Regulatory Agency (MHRA), alongside the European Commission, has granted a marketing authorization for the use of ofatumumab for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with RMS with active disease, defined by clinical or imaging features. It has the potential to become a recognized treatment option for eligible UK patients with RMS that can be self-administered, with initial guidance from an appropriately trained healthcare professional, once monthly at home via the...

To view this content, please register now for access

It's completely free